Cytek Biosciences, Inc.

CTKB Nasdaq SEC CIK 1831915
Follow Cytek Biosciences Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $53.2M +1.8% vs same quarter last year
Net income −$6.1M −11.3% vs same quarter last year
EPS, diluted -
Operating cash flow −$4.5M −14.2% vs same quarter last year
Revenue by quarter
$57.5M
$41.5M
$45.6M
$52.3M
$62.1M
$44.1M
$48.1M
$53.2M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
  • Revenue
  • Net income
−$100M$0$100M$200M$300MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$201.5M−$66.5M
FY24$200.5M−$6M
FY23$193M−$12.1M
FY22$164M$2.5M
FY21$128M$3M
FY20$92.8M$19.4M
FY19--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−50%−25%0%25%50%75%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2551.8%−20%−33%
FY2455.4%−10.2%−3%
FY2356.7%−14.4%−6.3%
FY2261.6%−1.1%1.5%
FY2161.9%7.2%2.4%
FY2055.7%14.7%20.9%
FY19---
Free cash flowOperating cash flow minus capital expenditure
−$40M−$20M$0$20M$40MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$8.8M
FY24$21.9M
FY23$633K
FY22−$22M
FY21$266K
FY20$13.6M
FY19-
Returned to shareholdersDividends paid and shares bought back
$0$20M$40M$60MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearBuybacks
FY25$15.1M
FY24$21.6M
FY23$44.2M
FY22$0
FY21$0
FY20-
FY19-
Net margin vs the sectorMedian of Technology companies filing with the SEC
  • Cytek Biosciences
  • Technology median
−40%−20%0%20%40%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearCytek BiosciencesTechnology median
FY25−33%−2.4%
FY24−3%−5%
FY23−6.3%−6.7%
FY221.5%−4.4%
FY212.4%−1.7%
FY2020.9%−3%
FY19-0%